REPROCELL Premium Seminar

Improving the Prediction of Clinical Safety, ADME and Efficacy by the Use of Human Fresh Tissues, 3D Models and Stem Cells

Dr. David C. Bunton

CEO, REPROCELL Europe Ltd.

【日時】2017年7月31日 (月) 15:00～18:30

14:45 開場 ／ 15:00~17:00 講演会･質疑応答 ／ 17:00~18:30 懇親会(立食形式)

場所

株式会社リプロセル

神奈川県横浜市港北区新横浜三丁目8-11
KDX新横浜381ビル 9階

[電車の場合]
JR新横浜駅北口より徒歩5分

Tel：045-475-3887

参加費

無料

※交通費は各自でのご負担となります

定員数

15名

※要予約

※定員数になり次第締め切らせていただきます。
※参加希望者多数の場合は定員数を増員する場合がございます。

REPROCELL discovery

お申込方法

お名前･ご所属･電話番号･メールアドレスを明記の上、メールにてお申込みください。ご質問等ございましたら、お気軽にご連絡ください。

株式会社リプロセル　営業･マーケティング部　高井　正人
TEL: 045-475-3882　E-Mail: masato.takai@reprocell.com

Title

Improving the Prediction of Clinical Safety, ADME and Efficacy by the Use of Human Fresh Tissues, 3D Models and Stem Cells.

Abstract

Twenty years on from the genomics revolution with many advances in our understanding of the human genome, the failure rate of drugs entering clinical trials continues to be around 90%. To try and improve clinical success rates, Pharma is adopting a “fail fast, fail early” approach, which requires preclinical models that accurately reflect the phenotype of human tissues. The advent of precision medicine is also driving an increase in the use of human tissues, patient-derived stem cells and disease-relevant 3D models to better understand the variation in drug response between patients.

Human disease-relevant tissue use is increasingly adopted to decrease clinical failures, particularly during phase II and III trials, where poor efficacy has been partly attributed to an over-reliance on animal models. Functional human tissue assays and complex tissues grown in 3D can bridge the gap between simple 2D cell-based studies, in vivo animal studies and clinical trials as they avoid species differences and, when sourced from patients or grown from patient-derived material, they can truly reflect the diverse patient population.

The presentation will review the challenges and benefits of using human tissues in drug development including REPROCELL’s tissue sourcing procedures, techniques and examples of how our data is used to better predict clinical effects.

Biography

Dr. David C. Bunton
CEO, REPROCELL Europe Ltd.

David is CEO of REPROCELL Europe, a life sciences company based in Glasgow, UK which is a subsidiary of REPROCELL Inc., Yokohama. ReproCELL is focused on providing services and products for drug discovery, including the early deployment of human cells and tissues in the development of precision medicines.

David founded the human tissue assay service leader Biopta Ltd in 2002 and took over as the CEO of the conjoint REPROCELL Europe business after the acquisition of Biopta through the REPROCELL Group where his focus remains on the use of human fresh tissues, 3D models and the use of iPSCs to better characterize drug efficacy and inter-patient variability in drug responses.

Previously a Lecturer at Glasgow Caledonian University, David has numerous publications in physiology and pharmacology to his name and is a respected opinion leader in the use of human tissue for drug discovery. He chairs the Scottish Lifesciences Association’s special interest group in precision medicine, is a member of the NC3Rs/MHRA working party on human tissues in safety pharmacology and is an advocate for the wider global use of human cells and tissues in drug development.